Anand Nishant, Stead Latha G
Department of Emergency Medicine, Mayo Clinic, Rochester, Minn. 55905, USA.
Cerebrovasc Dis. 2005;20(4):213-9. doi: 10.1159/000087701. Epub 2005 Aug 22.
To date, most work delineating the usefulness of neuron-specific enolase (NSE) as a marker for acute ischemic stroke has been inconclusive. This study had the following objectives: (1) to determine whether serum concentrations of NSE correlate with time of onset of stroke symptoms, volume of infarcted tissue, stroke severity, functional outcome, or length of hospital stay; (2) to determine whether serial measurements of NSE levels are useful markers for ongoing brain ischemia, and (3) to determine whether NSE levels at various time intervals are significantly higher in patients with stroke than in controls.
All abstracts and published full reports identified as potentially relevant by the literature search were independently assessed for inclusion in the review by each reviewer. Twelve studies (including 597 patients) satisfied the entry criteria for this qualitative analysis.
In 4 studies, time of onset of stroke symptoms was compared with time of first detectable NSE levels, which ranged from 4 to 8 h after stroke onset. In 7 studies, NSE levels increased with increased size of stroke, but in 2 studies there was no correlation. In the 2 studies that compared stroke severity with NSE levels, high NSE levels generally indicated worse outcome, but at low NSE levels the results were equivocal. In 7 studies, functional outcome at hospital dismissal and follow-up was compared with NSE levels; in 4, there was no correlation.
The serum level of NSE does seem to be higher in stroke patients than in controls, and it does appear to correlate with volume of infarcted tissue. However, it does not appear to correlate with functional outcome, and its relationship to stroke severity is unclear. This may be explained at least in part by the disparity in sampling times because the NSE level has been shown to peak after 24 h in most studies. Hence, the more delayed the sampling, the greater the correlation with stroke severity.
迄今为止,大多数关于神经元特异性烯醇化酶(NSE)作为急性缺血性中风标志物实用性的研究尚无定论。本研究有以下目标:(1)确定血清NSE浓度是否与中风症状发作时间、梗死组织体积、中风严重程度、功能结局或住院时间相关;(2)确定NSE水平的系列测量是否为持续脑缺血的有用标志物;(3)确定中风患者在不同时间间隔的NSE水平是否显著高于对照组。
每位评审员独立评估文献检索中确定为潜在相关的所有摘要和已发表的完整报告,以纳入本综述。十二项研究(包括597名患者)符合该定性分析的纳入标准。
在4项研究中,比较了中风症状发作时间与首次检测到NSE水平的时间,后者在中风发作后4至8小时之间。在7项研究中,NSE水平随中风规模增大而升高,但在2项研究中无相关性。在2项比较中风严重程度与NSE水平的研究中,高NSE水平通常表明结局较差,但在低NSE水平时结果不明确。在7项研究中,比较了出院时和随访时的功能结局与NSE水平;其中4项无相关性。
中风患者的血清NSE水平似乎确实高于对照组,且似乎与梗死组织体积相关。然而,它似乎与功能结局无关,其与中风严重程度的关系尚不清楚。这至少部分可以通过采样时间的差异来解释,因为在大多数研究中,NSE水平已显示在24小时后达到峰值。因此,采样越延迟,与中风严重程度的相关性就越大。